{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:12:09Z","timestamp":1761862329228},"reference-count":38,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2004,2,3]],"date-time":"2004-02-03T00:00:00Z","timestamp":1075766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Oral Pathology Medicine"],"published-print":{"date-parts":[[2004,3]]},"abstract":"<jats:p><jats:bold>Background:\u2002<\/jats:bold> Recurrent aphthous ulcerations (RAU) are common oral inflammatory lesions. Interleukin (IL)\u20108 is a pro\u2010inflammatory cytokine of host response to injury and inflammation. Our recent study has found that measurement of serum IL\u20106 level can detect only 24% RAU patients with an abnormal serum level. In this study, we examined both the serum IL\u20106 and IL\u20108 levels in a group of RAU patients. The abilities of IL\u20106 and IL\u20108 to detect patients with an abnormal serum level were compared in order to find out whether IL\u20108 was a more sensitive serum marker than IL\u20106 in monitoring the disease activity of RAU.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> In this study, we used a solid\u2010phase, two\u2010site sequential chemiluminescent immunometric assay to determine the baseline serum levels of IL\u20106 and IL\u20108 in 146 patients with RAU, 9 patients with traumatic ulcers (TU), and 54 normal control (NC) subjects. Eighty\u2010two RAU patients, with the serum IL\u20106 or IL\u20108 levels higher than the upper limit of normal serum concentration, were treated with levamisole for 0.5\u20133.5\u2003months, and their serum IL\u20106 and IL\u20108 levels were measured after treatment.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> We found that 25% (37\/146) RAU patients, as well as 33% (20\/61) major\u2010type, 19% (13\/69) minor\u2010type, and 25% (4\/16) herpetiform\u2010type RAU patients, had a serum level of IL\u20106 greater than the upper normal limit of 4.7\u2003pg\/ml. In contrast, 60% (87\/146) RAU patients, as well as 59% (36\/61) major\u2010type, 59% (41\/69) minor\u2010type, and 63% (10\/16) herpetiform\u2010type RAU patients, had a serum level of IL\u20108 greater than the upper normal limit of 8.7\u2003pg\/ml. In 82 RAU patients with the serum IL\u20106 or IL\u20108 levels higher than the upper limit of normal serum concentration, treatment with levamisole for a period of 0.5\u20133.5\u2003months could significantly reduce the serum IL\u20106 level from 12.0\u2003\u00b1\u20031.6 to 3.0\u2003\u00b1\u20030.5\u2003pg\/ml (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001), and could significantly lower the serum IL\u20108 level from 70.9\u2003\u00b1\u200311.2 to 13.8\u2003\u00b1\u20033.1\u2003pg\/ml (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001).<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> Because measurement of serum IL\u20108 level can detect 60% RAU patients with an abnormal serum level, while measurement of serum IL\u20106 level can detect only 25% RAU patients with an abnormal serum level, we conclude that serum IL\u20108 level is a more sensitive marker than serum IL\u20106 level in monitoring the disease activity of RAU. Levamisole can modulate both the serum IL\u20106 and IL\u20108 levels in RAU patients. IL\u20108, like IL\u20106, is also a useful serum marker in evaluating therapeutic effects of levamisole on RAU patients.<\/jats:p>","DOI":"10.1111\/j.0904-2512.2004.00094.x","type":"journal-article","created":{"date-parts":[[2004,2,3]],"date-time":"2004-02-03T10:34:48Z","timestamp":1075804488000},"page":"133-139","source":"Crossref","is-referenced-by-count":23,"title":["Serum interleukin\u20108 level is a more sensitive marker than serum interleukin\u20106 level in monitoring the disease activity of recurrent aphthous ulcerations"],"prefix":"10.1111","volume":"33","author":[{"given":"Andy","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu\u2010Fong","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean\u2010San","family":"Chia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun\u2010Pin","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,2,3]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"28","article-title":"Immunological aspects of recurrent oral ulcers: serum immunoglobulins, complements and antinuclear factor","volume":"2","author":"Sun A","year":"1983","journal-title":"Chin Dent J"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.1986.tb02921.x"},{"key":"e_1_2_5_4_2","first-page":"718","article-title":"Changes of T\u2010lymphocyte subset in recurrent aphthous ulcers","volume":"86","author":"Sun A","year":"1987","journal-title":"J Formos Med Assoc"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0030-4220(85)90287-7"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0714.1988.tb01539.x"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0714.1989.tb00735.x"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0030-4220(90)90329-Q"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-1229(91)90114-P"},{"key":"e_1_2_5_10_2","first-page":"510","article-title":"Immune\u2010inflammatory cells in recurrent oral ulcers (ROU)","volume":"99","author":"Hayrinen\u2010Immonen R","year":"1991","journal-title":"Scand J Dent Res"},{"key":"e_1_2_5_11_2","first-page":"222","article-title":"Immune\u2010activation in recurrent oral ulcers (ROU)","volume":"100","author":"Hayrinen\u2010Immonen R","year":"1992","journal-title":"Scand J Dent Res"},{"key":"e_1_2_5_12_2","first-page":"116","article-title":"Expression of interleukin\u20102 receptor by activated peripheral blood lymphocytes upregulated by the plasma level of interleukin\u20102 in patients with recurrent aphthous ulcers","volume":"24","author":"Sun A","year":"2000","journal-title":"Proc Natl Sci Counc ROC (B)"},{"key":"e_1_2_5_13_2","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1001\/archderm.1974.01630030021003","article-title":"Lymphocytotoxicity in aphthous stomatitis: lymphocytotoxicity for oral epithelial cells in recurrent aphthous stomatitis and Behcet syndrome","volume":"109","author":"Rogers RS","year":"1974","journal-title":"Arch Dermatol"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0714.2003.00096.x"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0030-4220(94)90087-6"},{"key":"e_1_2_5_16_2","first-page":"904","article-title":"Enhanced interleukin\u20108 secretion in circulation of patients with Behcet's disease","volume":"22","author":"Al\u2010Dalaan A","year":"1995","journal-title":"J Rheumatol"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004030050219"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.54.7.610"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004030000128"},{"key":"e_1_2_5_20_2","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1189\/jlb.72.5.847","article-title":"Multiple control of interleukin\u20108 gene expression","volume":"72","author":"Hoffmann E","year":"2002","journal-title":"J Leuk Biol"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/09629350220131935"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1159\/000018426"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.1994.tb01762.x"},{"key":"e_1_2_5_24_2","first-page":"1544","article-title":"Overproduction of monocyte\u2010derived tumor necrosis factor alpha, interleukin (IL)\u20106, IL\u20108 and increased neutrophil superoxide generation in Behcet's disease. A comparative study with familial Mediterranean fever and healthy subjects","volume":"20","author":"Mege JL","year":"1993","journal-title":"J Rheumatol"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.51.1.19"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(98)01370-0"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19801115)46:10<2185::AID-CNCR2820461015>3.0.CO;2-5"},{"key":"e_1_2_5_28_2","first-page":"347","article-title":"The levamisole story","volume":"20","author":"Janssen PA","year":"1976","journal-title":"Prog Drug Res"},{"key":"e_1_2_5_29_2","first-page":"31","article-title":"Potentiation of interleukin\u20102 activity by levamisole and imidazole","volume":"4","author":"Redondo JM","year":"1978","journal-title":"Immunol Lett"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0714.1994.tb01108.x"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0714.2002.310402.x"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.7.827"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0714.2000.290104.x"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0714.1992.tb00963.x"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.6.7.1532945"},{"key":"e_1_2_5_36_2","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1182\/blood.V81.10.2492.2492","article-title":"Activated platelets induce endothelial secretion of interleukin\u20108 in vitro via an interleukin\u20101\u2010mediated event","volume":"81","author":"Kaplanski G","year":"1993","journal-title":"Blood"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1177\/00220345960750110301"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gene.6363882"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0714.1996.tb01375.x"}],"container-title":["Journal of Oral Pathology &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.0904-2512.2004.00094.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.0904-2512.2004.00094.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T12:33:17Z","timestamp":1697027597000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.0904-2512.2004.00094.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2,3]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["10.1111\/j.0904-2512.2004.00094.x"],"URL":"https:\/\/doi.org\/10.1111\/j.0904-2512.2004.00094.x","archive":["Portico"],"relation":{},"ISSN":["0904-2512","1600-0714"],"issn-type":[{"value":"0904-2512","type":"print"},{"value":"1600-0714","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,2,3]]}}}